Table 2.

Baseline demographic and disease-related risk factors for the need to start DMARD therapy by 6 months and the diagnosis of RA at 12 months.

Demographic and Disease-related Risk FactorsDMARD OutcomeRA Outcome
nTrial Treatment-adjusted OR (95% CI)pOR Adjusted for Trial Treatment, Age, and Sex (95% CI)pnTrial Treatment-adjusted OR (95% CI)pOR Adjusted for Trial Treatment, Age, and Sex (95% CI)p
Age, yrs2531.01 (0.99–1.02)0.5432221.01 (0.99–1.03)0.420
Sex, women2530.68 (0.37–1.23)0.2052221.00 (0.57–1.78)0.992
Disease duration, wks2531.12 (0.66–1.93)0.6721.15 (0.67–1.98)0.6132221.61 (0.94–2.75)0.0851.60 (0.93–2.76)0.089
DAS28 (3)2471.54 (1.20–1.97)0.0011.58 (1.22–2.04)< 0.0012191.44 (1.12–1.84)0.0041.43 (1.11–1.84)0.005
VAS pain, per mm2431.02 (1.01–1.03)0.0011.02 (1.01–1.03)0.0012141.01 (1.00–1.03)0.0131.01 (1.00–1.03)0.012
VAS fatigue, per mm2431.01 (1.00–1.02)0.0131.02 (1.00–1.03)0.0052141.01 (1.00–1.02)0.0391.01 (1.00–1.02)0.022
VAS physician, per mm2511.02 (1.00–1.03)0.0151.02 (1.00–1.03)0.0132201.02 (1.01–1.04)0.0021.02 (1.01–1.04)0.002
RF-positive2474.00 (2.00–8.00)< 0.0014.31 (2.14– 8.70)< 0.0012199.48 (4.48–20.07)< 0.00110.33 (4.80–22.23)< 0.001
HAQ score2442.19 (1.42–3.39)< 0.0012.31 (1.49–3.60)< 0.0012151.82 (1.21–2.74)0.0041.83 (1.20–2.78)0.005
SF-36 PCS score2340.94 (0.90–0.98)0.0030.93 (0.89–0.98)0.0022060.98 (0.94–1.02)0.2460.98 (0.94–1.02)0.265
SF-36 MCS score2341.04 (0.90–1.08)0.1331.03 (0.99–1.08)0.1472061.01 (0.96–1.05)0.7631.00 (0.96–1.05)0.854
EQ-5D utility score2370.15 (0.05–0.44)0.0010.14 (0.05–0.41)< 0.0012100.32 (0.13–0.81)0.0170.32 (0.12–0.81)0.016
  • n: number of patients with available data. DMARD: disease-modifying antirheumatic drug; DAS28 (3): 28-joint count Disease Activity Score; VAS: visual analog scale; RF: rheumatoid factor; HAQ: Health Assessment Questionnaire; SF-36: Medical Outcomes Study Short-Form 36; PCS: SF-36 physical component summary score; MCS: SF-36 mental component summary score; EQ-5D: EuroQol-5D dimension utility score; RA: rheumatoid arthritis.